Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Combining RANK/RANKL and ERBB-2 targeting as a novel strategy in ERBB-2-positive breast carcinomas.

Zoi I, Karamouzis MV, Xingi E, Sarantis P, Thomaidou D, Lembessis P, Theocharis S, Papavassiliou AG.

Breast Cancer Res. 2019 Dec 3;21(1):132. doi: 10.1186/s13058-019-1226-9.

2.
3.

Multiplex RT-PCR-based detections of CEA, CK20 and EGFR in colorectal cancer patients.

Tsouma A, Aggeli C, Lembessis P, Zografos GN, Korkolis DP, Pectasides D, Skondra M, Pissimissis N, Tzonou A, Koutsilieris M.

World J Gastroenterol. 2010 Dec 21;16(47):5965-74.

4.

Detection of the circulating tumor cells in cancer patients.

Armakolas A, Panteleakou Z, Nezos A, Tsouma A, Skondra M, Lembessis P, Pissimissis N, Koutsilieris M.

Future Oncol. 2010 Dec;6(12):1849-56. doi: 10.2217/fon.10.152. Review.

PMID:
21142859
5.

Methods of detection of circulating melanoma cells: a comparative overview.

Nezos A, Msaouel P, Pissimissis N, Lembessis P, Sourla A, Armakolas A, Gogas H, Stratigos AJ, Katsambas AD, Koutsilieris M.

Cancer Treat Rev. 2011 Jun;37(4):284-90. doi: 10.1016/j.ctrv.2010.10.002. Epub 2010 Nov 23. Review.

PMID:
21106295
6.

CD40 expression and its association with low-grade inflammation in a Greek population of type 1 diabetic juveniles: evidence for differences in CD40 mRNA isoforms expressed by peripheral blood mononuclear cells.

Chatzigeorgiou AE, Lembessis PE, Mylona-Karagianni CF, Tsouvalas EA, Diamanti-Kandarakis E, Kamper EF.

Exp Clin Endocrinol Diabetes. 2010 Jan;118(1):38-46. doi: 10.1055/s-0029-1224151. Epub 2009 Oct 15.

PMID:
19834879
7.

IL-6 and PPARgamma signalling in human PC-3 prostate cancer cells.

Pitulis N, Papageorgiou E, Tenta R, Lembessis P, Koutsilieris M.

Anticancer Res. 2009 Jun;29(6):2331-7.

8.

The glutamatergic system expression in human PC-3 and LNCaP prostate cancer cells.

Pissimissis N, Papageorgiou E, Lembessis P, Armakolas A, Koutsilieris M.

Anticancer Res. 2009 Jan;29(1):371-7.

9.

Circulating tumor cells in colorectal cancer: detection methods and clinical significance.

Tsouma A, Aggeli C, Pissimissis N, Lembessis P, Zografos GN, Koutsilieris M.

Anticancer Res. 2008 Nov-Dec;28(6B):3945-60. Review.

10.

Detection of circulating tumor cells in bladder cancer patients.

Nezos A, Pissimisis N, Lembessis P, Sourla A, Dimopoulos P, Dimopoulos T, Tzelepis K, Koutsilieris M.

Cancer Treat Rev. 2009 May;35(3):272-9. doi: 10.1016/j.ctrv.2008.11.003. Epub 2008 Dec 21. Review.

PMID:
19103472
11.

Detection of circulating tumor cells in prostate cancer patients: methodological pitfalls and clinical relevance.

Panteleakou Z, Lembessis P, Sourla A, Pissimissis N, Polyzos A, Deliveliotis C, Koutsilieris M.

Mol Med. 2009 Mar-Apr;15(3-4):101-14. doi: 10.2119/molmed.2008.00116. Epub 2008 Dec 3. Review.

12.

Molecular markers detecting circulating melanoma cells by reverse transcription polymerase chain reaction: methodological pitfalls and clinical relevance.

Nezos A, Lembessis P, Sourla A, Pissimissis N, Gogas H, Koutsilieris M.

Clin Chem Lab Med. 2009;47(1):1-11. doi: 10.1515/CCLM.2009.009. Review.

PMID:
19055471
13.

The kisspeptin (KiSS-1)/GPR54 system in cancer biology.

Makri A, Pissimissis N, Lembessis P, Polychronakos C, Koutsilieris M.

Cancer Treat Rev. 2008 Dec;34(8):682-92. doi: 10.1016/j.ctrv.2008.05.007. Epub 2008 Jun 25. Review.

PMID:
18583061
14.

Molecular diagnosis of the viral component in cardiomyopathies: pathophysiological, clinical and therapeutic implications.

Halapas A, Pissimissis N, Lembessis P, Rizos I, Rigopoulos AG, Kremastinos DT, Koutsilieris M.

Expert Opin Ther Targets. 2008 Jul;12(7):821-36. doi: 10.1517/14728222.12.7.821 . Review.

PMID:
18554151
15.

Rosiglitazone attenuates insulin-like growth factor 1 receptor survival signaling in PC-3 cells.

Papageorgiou E, Pitulis N, Manoussakis M, Lembessis P, Koutsilieris M.

Mol Med. 2008 Jul-Aug;14(7-8):403-11. doi: 10.2119/2008-00021.Papageorgiou.

16.

Serum levels of the osteoprotegerin, receptor activator of nuclear factor kappa-B ligand, metalloproteinase-1 (MMP-1) and tissue inhibitors of MMP-1 levels are increased in men 6 months after acute myocardial infarction.

Halapas A, Zacharoulis A, Theocharis S, Karavidas A, Korres D, Papadopoulos K, Katopodis H, Stavropoulou A, Lembessis P, Xiromeritis C, Zacharoulis A, Koutsilieris M.

Clin Chem Lab Med. 2008;46(4):510-6. doi: 10.1515/CCLM.2008.091.

PMID:
18298349
17.

Combined androgen blockade therapy can convert RT-PCR detection of prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts from positive to negative in the peripheral blood of patients with clinically localized prostate cancer and increase biochemical failure-free survival after curative therapy.

Lembessis P, Msaouel P, Halapas A, Sourla A, Panteleakou Z, Pissimissis N, Milathianakis C, Bogdanos J, Papaioannou A, Maragoudakis E, Dardoufas C, Dimopoulos T, Koutsilieris M.

Clin Chem Lab Med. 2007;45(11):1488-94.

PMID:
17924845
18.
19.

The non-genomic crosstalk between PPAR-gamma ligands and ERK1/2 in cancer cell lines.

Papageorgiou E, Pitulis N, Msaouel P, Lembessis P, Koutsilieris M.

Expert Opin Ther Targets. 2007 Aug;11(8):1071-85. Review.

PMID:
17665979
20.

Regulation of the mGluR5, EAAT1 and GS expression by glucocorticoids in MG-63 osteoblast-like osteosarcoma cells.

Kalariti N, Lembessis P, Papageorgiou E, Pissimissis N, Koutsilieris M.

J Musculoskelet Neuronal Interact. 2007 Apr-Jun;7(2):113-8.

21.

Combination of somatostatin analogues and dexamethasone (anti-survival-factor concept) with luteinizing hormone-releasing hormone in androgen ablation-refractory prostate cancer with bone metastasis.

Koutsilieris M, Dimopoulos T, Milathianakis C, Bogdanos J, Karamanolakis D, Pissimissis N, Halapas A, Lembessis P, Papaioannou A, Sourla A.

BJU Int. 2007 Jul;100 Suppl 2:60-2. Review. No abstract available.

22.

Molecular detection of tyrosinase transcripts in peripheral blood from patients with malignant melanoma: correlation of PCR sensitivity threshold with clinical and pathologic disease characteristics.

Mitropapas G, Nezos A, Halapas A, Pissimissis N, Lembessis P, Sourla A, Vassilopoulos P, Koutsilieris M.

Clin Chem Lab Med. 2006;44(12):1403-9.

PMID:
17163814
23.

Serum testosterone: A potentially adjunct screening test for the assessment of the risk of prostate cancer among men with modestly elevated PSA values (> or =3.0 and <10.0 ng/ml).

Karamanolakis D, Lambou T, Bogdanos J, Milathianakis C, Sourla A, Lembessis P, Halapas A, Pissimissis N, Dessypris N, Petridou ET, Koutsilieris M.

Anticancer Res. 2006 Jul-Aug;26(4B):3159-66.

24.

Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach.

Koutsilieris M, Bogdanos J, Milathianakis C, Dimopoulos P, Dimopoulos T, Karamanolakis D, Halapas A, Tenta R, Katopodis H, Papageorgiou E, Pitulis N, Pissimissis N, Lembessis P, Sourla A.

Expert Opin Investig Drugs. 2006 Jul;15(7):795-804. Review.

PMID:
16787142
25.
26.

Bone microenvironment-related growth factors, zoledronic acid and dexamethasone differentially modulate PTHrP expression in PC-3 prostate cancer cells.

Tenta R, Sourla A, Lembessis P, Luu-The V, Koutsilieris M.

Horm Metab Res. 2005 Oct;37(10):593-601.

PMID:
16278781
27.

Molecular staging using qualitative RT-PCR analysis detecting thyreoglobulin mRNA in the peripheral blood of patients with differentiated thyroid cancer after therapy.

Karavitaki N, Lembessis P, Tzanela M, Vlassopoulou V, Thalassinos N, Koutsilieris M.

Anticancer Res. 2005 Jul-Aug;25(4):3135-42.

28.

Carotid body paraganglioma and SDHD mutation in a Greek family.

Liapis CD, Bellos JK, Halapas A, Lembessis P, Koutsilieris M, Kostakis A.

Anticancer Res. 2005 May-Jun;25(3c):2449-52.

29.

Cancer and bone repair mechanism: clinical applications for hormone refractory prostate cancer.

Koutsilieris M, Mitsiades C, Lembessis P, Sourla A.

J Musculoskelet Neuronal Interact. 2000 Sep;1(1):15-7.

30.

Three-dimensional type I collagen co-culture systems for the study of cell-cell interactions and treatment response in bone metastases.

Mitsiades C, Sourla A, Doillon C, Lembessis P, Koutsilieris M.

J Musculoskelet Neuronal Interact. 2000 Dec;1(2):153-5.

31.

Characterization of the glutametergic system in MG-63 osteoblast-like osteosarcoma cells.

Kalariti N, Lembessis P, Koutsilieris M.

Anticancer Res. 2004 Nov-Dec;24(6):3923-9.

33.

Three-dimensional type I collagen cell culture systems for the study of bone pathophysiology.

Themistocleous GS, Katopodis H, Sourla A, Lembessis P, Doillon CJ, Soucacos PN, Koutsilieris M.

In Vivo. 2004 Nov-Dec;18(6):687-96. Review.

34.

Male breast adenocarcinoma in a prostate cancer patient following prolonged anti-androgen monotherapy.

Karamanakos P, Mitsiades CS, Lembessis P, Kontos M, Trafalis D, Koutsilieris M.

Anticancer Res. 2004 Mar-Apr;24(2C):1077-81.

35.

Bone microenvironment-related growth factors modulate differentially the anticancer actions of zoledronic acid and doxorubicin on PC-3 prostate cancer cells.

Tenta R, Tiblalexi D, Sotiriou E, Lembessis P, Manoussakis M, Koutsilieris M.

Prostate. 2004 May 1;59(2):120-31.

PMID:
15042612
36.
37.
38.

Skeletal growth factor involvement in the regulation of fracture healing process.

Themistocleous GS, Kontou SE, Lembessis P, Katopodis HA, Kaseta MA, Themistocleous MS, Koutsilieris M.

In Vivo. 2003 Sep-Oct;17(5):489-503. Review.

PMID:
14598614
39.

Mutation analysis of BrCA1, BrCA2, and p53 versus soluble HLA class I and class II in a case of familial endometriosis.

Goumenou AG, Vassiliadis S, Matalliotakis IM, Koumantakis EG, Lembessis P, Koutsilieris M.

Fertil Steril. 2003 Feb;79(2):445-8.

PMID:
12568865
40.

Molecular evidence-based use of bone resorption-targeted therapy in prostate cancer patients at high risk for bone involvement.

Karamanolakis D, Bogdanos J, Sourla A, Milathianakis C, Tsintavis A, Lembessis P, Tenta R, Tiblalexi D, Koutsilieris M.

Mol Med. 2002 Nov;8(11):667-75. Review.

41.

Conversion of nested reverse-transcriptase polymerase chain reaction from positive to negative status at peripheral blood during androgen ablation therapy is associated with long progression-free survival in stage D2 prostate cancer patients.

Sourla A, Lembessis P, Mitsiades C, Dimopoulos T, Skouteris M, Metsinis M, Ntounis A, Ioannidis A, Katsoulis A, Kyragiannis V, Lambou T, Tsintavis A, Koutsilieris M.

Anticancer Res. 2001 Sep-Oct;21(5):3565-70.

PMID:
11848524
42.

Increased insulin-like growth factor 1 activity can rescue KLE endometrial-like cells from apoptosis.

Koutsilieris M, Mastrogamvrakis G, Lembessis P, Sourla A, Miligos S, Michalas S.

Mol Med. 2001 Jan;7(1):20-6.

43.

Novel approach to the molecular diagnosis of Marfan syndrome: application to sporadic cases and in prenatal diagnosis.

Toudjarska I, Kilpatrick MW, Lembessis P, Carra S, Harton GL, Sisson ME, Black SH, Stern HJ, Gelman-Kohan Z, Shohat M, Tsipouras P.

Am J Med Genet. 2001 Apr 1;99(4):294-302.

PMID:
11251996
45.

5-Oxo-6,8,11,14-eicosatetraenoic acid stimulates isotonic volume reduction of guinea pig jejunal crypt epithelial cells.

MacLeod RJ, Lembessis P, Hamilton JR, Powell WS.

J Pharmacol Exp Ther. 1999 Nov;291(2):511-6.

PMID:
10525065
46.

A novel G to A substitution at nucleotide 1734 of the FBN1 gene predicting a C534Y mutation responsible for marfan syndrome.

Kilpatrick MW, Lembessis P, Rose E, Tsipouras P.

Hum Hered. 1999 Jun;49(3):176-7. No abstract available.

PMID:
10364683
48.

Disruption of human limb morphogenesis by a dominant negative mutation in CDMP1.

Thomas JT, Kilpatrick MW, Lin K, Erlacher L, Lembessis P, Costa T, Tsipouras P, Luyten FP.

Nat Genet. 1997 Sep;17(1):58-64.

PMID:
9288098
49.

The isolation and characterization of a novel corticostatin/defensin-like peptide from the kidney.

Bateman A, MacLeod RJ, Lembessis P, Hu J, Esch F, Solomon S.

J Biol Chem. 1996 May 3;271(18):10654-9.

50.

Sodium-bicarbonate cotransport in guinea pig ileal crypt cells.

MacLeod RJ, Redican F, Lembessis P, Hamilton JR, Field M.

Am J Physiol. 1996 Mar;270(3 Pt 1):C786-93.

PMID:
8638658

Supplemental Content

Loading ...
Support Center